Analysis of the DEA post-hearing brief on proposed Schedule III placement
A specialist regulatory publication discusses the DEA filing. This is commentary on an ongoing process, not a final regulatory decision.
Read →Items are included for professional information. Inclusion does not constitute endorsement by the Institute. Source types are identified so that company, industry and commentary material is not presented as equivalent to peer-reviewed research.
A specialist regulatory publication discusses the DEA filing. This is commentary on an ongoing process, not a final regulatory decision.
Read →Industry reporting describes disagreement concerning proposed reimbursement and insurance arrangements in Germany; it is not an official regulatory statement.
Read →A randomised, placebo-controlled trial studied a defined, standardised cannabis extract in adults with chronic low back pain. Findings should not be generalised to other products, formulations, indications or populations.
Read →The announcement concerns a defined cannabidiol intervention and a particular nerve-injury population; it does not establish effects for all cannabis products or pain conditions.
Read →The Australian regulator outlines its response to a review of unapproved medicinal cannabis products and current access pathways.
Read →A company update concerning production capacity and the German market. Company announcements are identified separately from independent research and regulatory sources, and do not constitute product promotion.
Read →